Editors Note
Two antisense results landed within 48 hours of each other, and together they mark where RNA medicine currently earns its keep. Novartis lowered lipoprotein(a) as designed in 8,323 patients and still missed the cardiovascular endpoint. Ionis won approval for the first therapy in Alexander disease, where the target and the disease are effectively the same thing. The distance between those outcomes is causal certainty, not chemistry. Elsewhere, capital kept moving — Lilly spent again outside obesity — while the SEC and FDA formalised how they share what companies tell regulators against what they tell investors.
Top Stories
Novartis Reports Pelacarsen Phase 3 Miss in 8,323 Patients
BioIntel – September 5, 2026
Summary:
Novartis said pelacarsen, an Ionis-partnered antisense oligonucleotide, failed to reduce heart attack, stroke or other major cardiovascular events in the Phase 3 Lp(a)Horizon trial, despite lowering lipoprotein(a) as intended. The trial enrolled 8,323 patients with elevated Lp(a) who had established cardiovascular disease or a prior event. Chief medical officer Shreeram Aradhye said lower Lp(a) levels were observed, but did not translate into reduced cardiovascular risk across the study population. Novartis has not released full data and plans to present at an upcoming medical meeting, leaving open whether the result was essentially neutral or directionally positive without reaching significance.
Why it matters:
Pelacarsen was the first late-stage test of whether lowering Lp(a) changes outcomes rather than a biomarker. The miss raises the evidentiary bar for every programme still pursuing the target, and moves the next inflection to deeper-suppression candidates.
Ionis Wins FDA Approval for Zanvastro in Alexander Disease
BioIntel – September 4, 2026
Summary:
The FDA approved Zanvastro, formerly zilganersen, as the first disease-modifying treatment for Alexander disease, an ultrarare genetic leukodystrophy that previously had no approved options. The decision arrived more than two weeks ahead of the September 22 PDUFA date and gives Ionis its first independent neurology launch. In a Phase 3 trial enrolling 49 patients aged five and older, a 50-mg dose produced statistically significant stabilisation of gait speed on the 10-metre walk test at week 61 against untreated patients. Lead investigator Amy Waldman of Children's Hospital of Philadelphia noted that stability, not reversal of neurologic damage, is the realistic goal.
Why it matters:
Ionis built its neurology credibility through partnered medicines; this is the first it commercialises alone. An approved product establishes field teams and treatment-centre relationships that support later rare-neurology launches, independent of Alexander disease's very small population.
Eli Lilly Strikes Up to $2.875 Billion Merida Deal
BioIntel – September 1, 2026
Summary:
Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash, adding autoimmune and allergic disease programmes built on selective degradation of pathogenic autoantibodies. Lilly did not break out upfront against contingent milestones; closing is expected in the fourth quarter pending clearances. The lead programme, MER511, is in Phase 1 for thyroid eye disease and Graves' disease, where Lilly said initial data show robust reductions in thyroid-stimulating antibodies. The deal also brings MER769, a preclinical antibody programme, and Merida's precision degradation platform. BMO Capital Markets described the acquisition as a strategic use of capital diversifying Lilly's immunology pipeline.
Why it matters:
Lilly has committed more than $25 billion to business development in roughly six months. Buying platform biology rather than a single asset signals continued willingness to spend outside obesity, where one mechanism can support several programmes.
SEC and FDA Sign Three-Year Information-Sharing Pact
BioIntel – September 2, 2026
Summary:
The SEC and the FDA signed a three-year memorandum of understanding creating a formal mechanism for sending information requests, sharing non-public information and assigning points of contact. SEC Chairman Paul S. Atkins said FDA-related disclosures by public companies have a significant impact on markets; Acting FDA Commissioner Kyle Diamantas framed the pact as protecting patients and public trust. Pillsbury partner David Oliwenstein, formerly senior counsel in the SEC's market abuse unit, said the agreement signals continued scrutiny of biopharma insider trading, should make technically complex investigations more efficient, and reflects a judgment that the sector carries substantial misconduct risk.
Why it matters:
Disclosure risk now extends past careful press-release drafting to whether public statements match FDA-facing reality. For companies whose material information emerges through trial progress and regulatory feedback, the two agencies' line of sight just shortened.
Truist Says Biotech Rebound Reached $136 Billion in Deals
BioIntel – September 4, 2026
Summary:
A Truist Securities note said biotech's recovery is now visible across public markets, private financing and acquisitions at once. By the firm's own count, M&A reached $136 billion across 57 deals, already clearing the total number of deals in 2025, while first-half IPO issuance hit $5.9 billion across 21 debuts against $1.54 billion for all of 2025. Truist said the XBI ended the first half up 34% year to date, and that companies trading below cash fell to 15% from 22%. It attributed the rebound to patent-cliff pressure, an open financing window and a more supportive regulatory backdrop.
Why it matters:
A rebound running through four channels at once is more durable than one driven by takeovers alone. For private companies, it indicates buyers and capital providers are again pricing pipeline value earlier than they did through the downturn.
Medtronic Recalls Bravo CF Delivery Devices After 184 Serious Injuries
BioIntel – September 2, 2026
Summary:
Medtronic is recalling esophageal pH monitoring capsule delivery devices tied to its Bravo CF capsule after the FDA said the capsule may not attach to the patient's esophagus, or may detach from the delivery device, as intended. Medtronic wrote to customers on August 6 and the FDA followed with an early alert; as of August 10 the company had reported 184 serious injuries and no deaths. Potential risks include hemorrhaging, airway obstruction and lacerations. A subset of lots was covered by a June 2025 recall for the same failure, which Medtronic says had a different underlying cause.
Why it matters:
The repeat failure mode, not the injury count, is the signal. Endoscopy centres face a second deployment problem on the same product, which raises procurement and operational questions well beyond an isolated lot.
Market & Investment Pulse
Capital is moving through four channels at once, not one. Truist counts $136 billion in M&A across 57 deals and $5.9 billion of first-half IPO issuance, against $1.54 billion for all of 2025, with companies trading below cash down to 15% from 22%.
Large-cap buyers are still paying for mechanism rather than near-term revenue. Lilly's up-to-$2.875 billion Merida purchase targets a platform whose lead asset is in Phase 1, and follows more than $25 billion committed to business development in roughly six months.
Failure is repricing fields, not just assets. Pelacarsen's miss moves the next Lp(a) inflection to RNA interference candidates from Amgen and Eli Lilly, reported to lower Lp(a) by more than 90% against roughly 72% for pelacarsen. Analysts at William Blair and Citi both declined to call the mechanism dead.
Regulatory throughput is holding. Truist counted 36 novel approvals from CDER through August 28, ten of them through the Commissioner's National Priority Review Program — a pattern Ionis's early Zanvastro clearance fits.
Enforcement risk is rising even as approval risk eases. The SEC–FDA pact ties disclosure practice to trial conduct at exactly the moment more companies are financing against clinical milestones.
What to Watch Next Week
Full Lp(a)Horizon data at an upcoming medical meeting, which should establish whether the result was neutral or directional.
Ionis advancing obudanersen in Angelman syndrome through the Phase 3 REVEAL study, after Ultragenyx's apazunersen failed its own Phase 3.
Closing of Lilly's Merida acquisition, expected in the fourth quarter pending clearances.
Any further FDA action on the Bravo CF recall following its early alert.
Thank you for reading BioIntel Weekly Brief!
Every story above is drawn from BioIntel reporting published this week. The through-line is that certainty — not capability — is what the market is currently paying for: in trial design, in disclosure practice, and in what buyers are willing to fund. Read the full analysis at thebiointel.com.